Enveric Biosciences, Inc.: Form 10-K/A for the period ended Dec 31, 2022
Filed with the SEC on Jun 9, 2023 and accepted by EDGAR at Jun 8, 2023, 18:49 ET.
Sections
No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2022-01-01 to 2022-12-31 | $8.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2022-01-01 to 2022-12-31 | −$27.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2022-01-01 to 2022-12-31 | $5.2k | us-gaap:InterestExpense |
| Income tax | 12 months2022-01-01 to 2022-12-31 | −$1.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2022-01-01 to 2022-12-31 | −$18.5m | us-gaap:NetIncomeLoss |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | −$13.00 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | −$17.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | $584.2k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-12-31 | $17.7m | us-gaap:Cash |
| Current assets | At period end2022-12-31 | $18.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $19.6m | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $4.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $4.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-12-31 | $14.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-23-020625. Last ingested by Listed: Nov 14, 2026, 20:02 ET. Listed shows no prices and gives no investment advice.